Lyra Therapeutics (LYRA) Income from Continuing Operations (2021 - 2025)
Historic Income from Continuing Operations for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$6.0 million.
- Lyra Therapeutics' Income from Continuing Operations rose 4959.99% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.9 million, marking a year-over-year increase of 6624.7%. This contributed to the annual value of -$93.4 million for FY2024, which is 4906.67% down from last year.
- According to the latest figures from Q3 2025, Lyra Therapeutics' Income from Continuing Operations is -$6.0 million, which was up 4959.99% from -$7.4 million recorded in Q2 2025.
- Lyra Therapeutics' 5-year Income from Continuing Operations high stood at -$6.0 million for Q3 2025, and its period low was -$48.1 million during Q2 2024.
- In the last 5 years, Lyra Therapeutics' Income from Continuing Operations had a median value of -$13.6 million in 2021 and averaged -$14.6 million.
- As far as peak fluctuations go, Lyra Therapeutics' Income from Continuing Operations plummeted by 20817.65% in 2024, and later soared by 8454.84% in 2025.
- Over the past 5 years, Lyra Therapeutics' Income from Continuing Operations (Quarter) stood at -$13.6 million in 2021, then decreased by 4.44% to -$14.2 million in 2022, then fell by 6.57% to -$15.2 million in 2023, then increased by 27.56% to -$11.0 million in 2024, then surged by 45.5% to -$6.0 million in 2025.
- Its Income from Continuing Operations stands at -$6.0 million for Q3 2025, versus -$7.4 million for Q2 2025 and -$8.5 million for Q1 2025.